Literature DB >> 25720323

MicroRNA deep-sequencing reveals master regulators of follicular and papillary thyroid tumors.

Veronika Mancikova1, Esmeralda Castelblanco2, Elena Pineiro-Yanez3, Javier Perales-Paton3, Aguirre A de Cubas1, Lucia Inglada-Perez4, Xavier Matias-Guiu5, Ismael Capel6, Maria Bella7, Enrique Lerma8, Garcilaso Riesco-Eizaguirre9, Pilar Santisteban10, Francisco Maravall2, Didac Mauricio11, Fatima Al-Shahrour3, Mercedes Robledo4.   

Abstract

MicroRNA deregulation could be a crucial event in thyroid carcinogenesis. However, current knowledge is based on studies that have used inherently biased methods. Thus, we aimed to define in an unbiased way a list of deregulated microRNAs in well-differentiated thyroid cancer in order to identify diagnostic and prognostic markers. We performed a microRNA deep-sequencing study using the largest well-differentiated thyroid tumor collection reported to date, comprising 127 molecularly characterized tumors with follicular or papillary patterns of growth and available clinical follow-up data, and 17 normal tissue samples. Furthermore, we integrated microRNA and gene expression data for the same tumors to propose targets for the novel molecules identified. Two main microRNA expression profiles were identified: one common for follicular-pattern tumors, and a second for papillary tumors. Follicular tumors showed a notable overexpression of several members of miR-515 family, and downregulation of the novel microRNA miR-1247. Among papillary tumors, top upregulated microRNAs were miR-146b and the miR-221~222 cluster, while miR-1179 was downregulated. BRAF-positive samples displayed extreme downregulation of miR-7 and -204. The identification of the predicted targets for the novel molecules gave insights into the proliferative potential of the transformed follicular cell. Finally, by integrating clinical follow-up information with microRNA expression, we propose a prediction model for disease relapse based on expression of two miRNAs (miR-192 and let-7a) and several other clinicopathological features. This comprehensive study complements the existing knowledge about deregulated microRNAs in the development of well-differentiated thyroid cancer and identifies novel markers associated with recurrence-free survival.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25720323     DOI: 10.1038/modpathol.2015.44

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  38 in total

Review 1.  Applications of next-generation sequencing technologies in functional genomics.

Authors:  Olena Morozova; Marco A Marra
Journal:  Genomics       Date:  2008-08-24       Impact factor: 5.736

2.  The role of microRNA genes in papillary thyroid carcinoma.

Authors:  Huiling He; Krystian Jazdzewski; Wei Li; Sandya Liyanarachchi; Rebecca Nagy; Stefano Volinia; George A Calin; Chang-Gong Liu; Kaarle Franssila; Saul Suster; Richard T Kloos; Carlo M Croce; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

3.  MicroRNA-204/211 alters epithelial physiology.

Authors:  Fei E Wang; Connie Zhang; Arvydas Maminishkis; Lijin Dong; Connie Zhi; Rong Li; Jing Zhao; Vladimir Majerciak; Arti B Gaur; Shan Chen; Sheldon S Miller
Journal:  FASEB J       Date:  2010-01-07       Impact factor: 5.191

4.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

5.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

6.  Regularization Paths for Generalized Linear Models via Coordinate Descent.

Authors:  Jerome Friedman; Trevor Hastie; Rob Tibshirani
Journal:  J Stat Softw       Date:  2010       Impact factor: 6.440

7.  Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information.

Authors:  C Montero-Conde; J M Martín-Campos; E Lerma; G Gimenez; J L Martínez-Guitarte; N Combalía; D Montaner; X Matías-Guiu; J Dopazo; A de Leiva; M Robledo; D Mauricio
Journal:  Oncogene       Date:  2007-09-17       Impact factor: 9.867

Review 8.  Classification of follicular cell-derived thyroid cancer by global RNA profiling.

Authors:  Maria Rossing
Journal:  J Mol Endocrinol       Date:  2013-03-18       Impact factor: 5.098

9.  MicroRNA-mediated networks underlie immune response regulation in papillary thyroid carcinoma.

Authors:  Chen-Tsung Huang; Yen-Jen Oyang; Hsuan-Cheng Huang; Hsueh-Fen Juan
Journal:  Sci Rep       Date:  2014-09-29       Impact factor: 4.379

10.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.

Authors:  Mark D Robinson; Davis J McCarthy; Gordon K Smyth
Journal:  Bioinformatics       Date:  2009-11-11       Impact factor: 6.937

View more
  18 in total

1.  Genome-wide cross-cancer analysis illustrates the critical role of bimodal miRNA in patient survival and drug responses to PI3K inhibitors.

Authors:  Laura Moody; Guanying Bianca Xu; Yuan-Xiang Pan; Hong Chen
Journal:  PLoS Comput Biol       Date:  2022-05-31       Impact factor: 4.779

2.  MicroRNA-1179 inhibits glioblastoma cell proliferation and cell cycle progression via directly targeting E2F transcription factor 5.

Authors:  Xiupeng Xu; Ning Cai; Tongle Zhi; Zhongyuan Bao; Dong Wang; Yinlong Liu; Kuan Jiang; Liang Fan; Jing Ji; Ning Liu
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

Review 3.  Non-Coding RNAs in Thyroid Cancer.

Authors:  Ranran Zhang; Heather Hardin; Jidong Chen; Zhenying Guo; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

Review 4.  miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.

Authors:  Emanuela Minna; Paola Romeo; Matteo Dugo; Loris De Cecco; Katia Todoerti; Silvana Pilotti; Federica Perrone; Ettore Seregni; Luca Agnelli; Antonino Neri; Angela Greco; Maria Grazia Borrello
Journal:  Oncotarget       Date:  2016-03-15

5.  New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.

Authors:  Manuel Saiselet; David Gacquer; Alex Spinette; Ligia Craciun; Myriam Decaussin-Petrucci; Guy Andry; Vincent Detours; Carine Maenhaut
Journal:  BMC Genomics       Date:  2015-10-21       Impact factor: 3.969

Review 6.  miRNA expression and function in thyroid carcinomas: a comparative and critical analysis and a model for other cancers.

Authors:  Manuel Saiselet; Jaime M Pita; Alice Augenlicht; Geneviève Dom; Maxime Tarabichi; Danai Fimereli; Jacques E Dumont; Vincent Detours; Carine Maenhaut
Journal:  Oncotarget       Date:  2016-08-09

Review 7.  Molecular Signature of Indeterminate Thyroid Lesions: Current Methods to Improve Fine Needle Aspiration Cytology (FNAC) Diagnosis.

Authors:  Silvia Cantara; Carlotta Marzocchi; Tania Pilli; Sandro Cardinale; Raffaella Forleo; Maria Grazia Castagna; Furio Pacini
Journal:  Int J Mol Sci       Date:  2017-04-06       Impact factor: 5.923

8.  Prognostic Value of MicroRNAs in Preoperative Treated Rectal Cancer.

Authors:  Azadeh Azizian; Ingo Epping; Frank Kramer; Peter Jo; Markus Bernhardt; Julia Kitz; Gabriela Salinas; Hendrik A Wolff; Marian Grade; Tim Beißbarth; B Michael Ghadimi; Jochen Gaedcke
Journal:  Int J Mol Sci       Date:  2016-04-15       Impact factor: 5.923

Review 9.  Candidate microRNAs as biomarkers of thyroid carcinoma: a systematic review, meta-analysis, and experimental validation.

Authors:  Yiren Hu; Hui Wang; Ende Chen; Zhifeng Xu; Bi Chen; Guowen Lu
Journal:  Cancer Med       Date:  2016-07-27       Impact factor: 4.452

10.  MiR-150 Inhibits Cell Growth In Vitro and In Vivo by Restraining the RAB11A/WNT/β-Catenin Pathway in Thyroid Cancer.

Authors:  Dongfang Bai; Haipeng Sun; Xiaodong Wang; Hongliang Lou; Jian Zhang; Xiaohong Wang; Ling Jiang
Journal:  Med Sci Monit       Date:  2017-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.